title: [Hemato-oncological imaging : Importance of hybrid procedures].
abstract: OBJECTIVE
  Biomedical imaging procedures play a major role in hemato-oncological diseases with respect to pre-therapeutic staging and assessment of treatment response.
  
  
  METHODS
  Originally, the therapeutic management was the domain of computed tomography (CT) and whole-body magnetic resonance imaging (MRI).
  
  
  METHODS
  Over the last decade these purely morphological techniques have gradually been replaced by hybrid imaging techniques, such as positron emission tomography-CT (PET/CT) and PET/MRI, which also provide metabolic and functional information.
  
  
  METHODS
  For lymphomas, the PET tracer 18F-fluorodeoxyglucose (18 F-FDG) is meanwhile so well-established that its use is a cornerstone of the Lugano classification; however, for multiple myeloma the search for an optimal PET tracer that can also detect early disease stages is still ongoing. Functional MRI techniques, such as diffusion-weighted imaging (DWI), perfusion-weighted imaging and dynamic contrast-enhanced imaging have shown promising results for both lymphomas and multiple myelomas.
  
  
  RESULTS
  The PET/MRI technique can combine the different types of information due to its truly multiparametric approach.
  
  
  CONCLUSIONS
  In the future PET/MRI could possibly become the hybrid imaging technique of choice for hemato-oncological diseases.
authors.affiliation: Abteilung für Allgemeine und Kinderradiologie, Medizinische Universität Wien, Univ.-Klinik für Radiologie und Nuklearmedizin, Waehringer Guertel 18-20, 1090, Wien, Österreich. marius.mayerhoefer@meduniwien.ac.at.
authors.forename: M E
authors.initials: ME
authors.lastname: Mayerhoefer
authors.affiliation: Abteilung für Nuklearmedizin, Medizinische Universität Wien, Univ.-Klinik für Radiologie und Nuklearmedizin, Wien, Österreich.
authors.forename: A
authors.initials: A
authors.lastname: Haug
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D003937:Diagnosis, Differential; D019337:Hematologic Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D057054:Molecular Imaging / Q000379:methods*; D064847:Multimodal Imaging / Q000379:methods; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D014055:Tomography, Emission-Computed / Q000379:methods*
chemical_list: D014408:Biomarkers, Tumor; D019275:Radiopharmaceuticals
keywords: 18F Fluorodeoxyglucose; Multiparametric approach; Positron emission tomography; Staging; Therapy response